Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform. CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire/ ...

Neurodegenerative diseases pose a serious threat to public health, with an increasing impact among the elderly population.

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other ...

Ancient Viral DNA in the Human Genome Linked to Multiple Sclerosis and Amyotrophic Lateral Sclerosis Oct. 21, 2024 — New research has revealed a connection between ancient viral DNA embedded in ...

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...

The number of ALS cases in the U.S. is expected to increase by over 10% by 2030, as compared with 2022 prevalence rates, per ...

A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.